Key facts
- The U.S. FDA approved Sanofi's Sarclisa in a wearable injector form.
- The drug is for patients with multiple myeloma, a rare blood cancer.
- The wearable injector allows for subcutaneous delivery, reducing infusion center time.
- The intravenous form of Sarclisa was first approved in 2020.
The U.S. Food and Drug Administration has approved a wearable injector form of Sanofi's blood cancer drug, Sarclisa, providing an alternative to intravenous infusions for patients with multiple myeloma. The new formulation, Sarclisa Escena, utilizes an on-body injector device for subcutaneous delivery.
This approval represents a regulatory win for the French drugmaker as it aims to bolster its drug pipeline. The subcutaneous dosing is expected to reduce the time patients spend at infusion centers and ease the burden on oncology clinics and nursing staff. The intravenous version of Sarclisa initially received FDA approval in 2020 for patients with relapsed multiple myeloma.